- Home
- OCSL vs SPRY Comparison
OCSL vs SPRY Comparison
Compare OCSL & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCSL
- SPRY
- Stock Information
- Founded
- OCSL 2007
- SPRY 2015
- Country
- OCSL United States
- SPRY United States
- Employees
- OCSL N/A
- SPRY N/A
- Industry
- OCSL Finance: Consumer Services
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- OCSL Finance
- SPRY Health Care
- Exchange
- OCSL Nasdaq
- SPRY Nasdaq
- Market Cap
- OCSL 1.3B
- SPRY 1.4B
- IPO Year
- OCSL 2008
- SPRY N/A
- Fundamental
- Price
- OCSL $14.45
- SPRY $14.53
- Analyst Decision
- OCSL Hold
- SPRY Strong Buy
- Analyst Count
- OCSL 7
- SPRY 4
- Target Price
- OCSL $16.00
- SPRY $28.75
- AVG Volume (30 Days)
- OCSL 525.5K
- SPRY 1.5M
- Earning Date
- OCSL 07-31-2025
- SPRY 08-05-2025
- Dividend Yield
- OCSL 13.78%
- SPRY N/A
- EPS Growth
- OCSL N/A
- SPRY N/A
- EPS
- OCSL 0.11
- SPRY N/A
- Revenue
- OCSL $353,866,000.00
- SPRY $97,122,000.00
- Revenue This Year
- OCSL N/A
- SPRY N/A
- Revenue Next Year
- OCSL N/A
- SPRY $140.40
- P/E Ratio
- OCSL $132.91
- SPRY N/A
- Revenue Growth
- OCSL N/A
- SPRY 971120.00
- 52 Week Low
- OCSL $12.50
- SPRY $7.55
- 52 Week High
- OCSL $19.80
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- OCSL 53.50
- SPRY 53.77
- Support Level
- OCSL $13.92
- SPRY $13.28
- Resistance Level
- OCSL $14.72
- SPRY $14.87
- Average True Range (ATR)
- OCSL 0.24
- SPRY 0.77
- MACD
- OCSL 0.01
- SPRY -0.04
- Stochastic Oscillator
- OCSL 66.25
- SPRY 56.31
About OCSL Oaktree Specialty Lending Corporation
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.